Pulmonary Medicine

Host: Gerard A. Silvestri MD, MS, Master FCCP

Guest: Fabien Maldonado, MD, FCCP

Guest: Adam H. Fox, MD, MSc

Cutting-edge biopsy methods and streamlined biomarker testing are transforming early-stage non-small cell lung cancer (NSCLC) care. Hear from Drs. Gerard Silvestri, Fabien Maldonado, and Adam Fox as they discuss the evolution of bronchoscopic techniques, insights from landmark trials, and the role of pragmatic clinical research in refining biopsy approaches. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina; Dr. Maldonado is a Professor of Medicine and Thoracic Surgery, the Pierre Massion Director in Lung Cancer Research, and the Director of Interventional Pulmonology Research at Vanderbilt University; and Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina.

This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Host: Gerard A. Silvestri MD, MS, Master FCCP

Guest: Jeffrey B. Velotta, MD, FACS

Guest: Anne Gonzalez, MD, M.Sc.

For patients with non-small cell lung cancer, staging accuracy is critical in guiding treatment decisions that can significantly affect outcomes. In this expert-led discussion, Dr. Gerard Silvestri sits down with Drs. Anne Gonzalez and Jeffrey Velotta break down what clinicians need to know, including how to perform thorough EBUS staging, why PET scans alone aren’t enough, and what the updated TNM classification means for surgical planning. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina; Dr. Gonzalez is a pulmonary and critical care physician, a researcher in the Translational Research and Respiratory Diseases Program, and an Associate Professor in the Department of Medicine at McGill University in Montreal; and Dr. Velotta is a leading thoracic surgeon specializing in complex cancers, a Clinical Professor in the Department of Clinical Science at the Kaiser Permanente Bernard J. Tyson School of Medicine, and a Clinical Assistant Professor in the Department of Surgery at UCSF School of Medicine in California.

This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Immune imprinting refers to how the immune system's first encounter with a virus, such as influenza, leaves a lasting imprint that shapes future immune responses.1,2 However, influenza vaccines may affect this process—particularly when egg-based ones are used. Tune in to learn about the impact of immune imprinting, the role that vaccines play in this process, and how switching to non-egg-based vaccines could help redirect immune responses and possibly create more effective defenses in people of all ages.3,4

References:

1. King SM, Bryan SP, Hilchey SP, Wang J, Zand MS. First impressions matter: Immune imprinting and antibody cross-reactivity in influenza and SARS-CoV-2. Pathogens. 2023;12(2):169. doi:10.3390/pathogens12020169
2. Zhang A, Stacey HD, Mullarkey CE, Miller MS. Original antigenic sin: How first exposure shapes lifelong anti-influenza virus immune responses. J Immunol. 2019;202(2):335–340. doi:10.4049/jimmunol.1801149
3. Rockman S, Laurie K, Ong C, et al. Cell-based manufacturing technology increases antigenic match of influenza vaccine and results in improved effectiveness. Vaccines (Basel). 2022;11(1):52. doi:10.3390/vaccines11010052
4. Liu F, Gross FL, Jefferson SN, et al. Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination. J Clin Invest. 2021;131(8):e146138. doi:10.1172/JCI146138

USA-CRP-24-0038 July 2025

Guest: Martha Kingman, DNP, FNP-C

Guest: Ioana Preston, MD

Guest: Jean M. Elwing, MD

Pulmonary arterial hypertension (PAH) is a serious, progressive condition and successfully managing patients can present certain challenges. Treatment selection is multifactorial and often involves the consideration of myriad patient factors, including WHO Group, objective risk stratification score, cardiac functioning on imaging, and shared decision-making. And while all patients who are living with PAH require careful evaluation, those with comorbidities and/or psychosocial challenges can require additional consideration when developing a treatment plan that improves outcomes.

Guest: Vallerie V. McLaughlin, MD

Guest: Ioana Preston, MD

Guest: Kelly Chin, MD, MSCA

Pulmonary arterial hypertension (PAH) is a serious, progressive condition that involves making the correct diagnosis and identifying patient comorbidities as important first steps to creating a successful treatment approach. And while identifying which WHO Group a patient belongs to is key, part of the art of treating PAH is recognizing that many patients can have overlap between groups. Our experts’ insights can help you elevate your practice and develop effective PAH treatment plans.

Guest: Jorge Nieva, MD

Can the immune checkpoint inhibitor atezolizumab be safely administered subcutaneously at home for patients with non-small cell lung cancer (NSCLC)? That’s the exact question an ongoing study is seeking to answer, and here to discuss the study’s objective, design, and potential implications for home-based subcutaneous cancer therapies is Dr. Jorge Nivea. He’s an Associate Professor of Clinical Medicine at the University of Southern California’s Keck School of Medicine.

Guest: Jessica Shull, PhD

Guest: Joshua Solomon, MD

Host: Ryan Quigley

Patients with pulmonary fibrosis often face anxiety and emotional distress that go unadressed during their care. Given this unmet need, a digital cognitive behavioral therapy (CBT) platform was designed to support emotional wellbeing alonside medical treatment. Mr. Ryan Quigley sits down with Drs. Jessica Shull and Joshua Solomon, who presented at the 2025 American Thoracic Society International Conference to explore how this platform may enhance quality of life, support therapy adherence, and integrate into routine care. Dr. Shull is the Director of Digital Health and a Clinical Science Liaison at Vicore Pharma, and Dr. Solomon is a Professor of Medicine in Pulmonary Care and the Director of the Interstitial Lung Disease Program at National Jewish Health.

Host: Jacob Sands, MD

Guest: Elaine Shum, MD

Guest: Estelamari Rodriguez, MD, MPH

There was a recent pooled analysis of the TROPION-Lung01 and TROPION-Lung05 studies, which focused on the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients with previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC). According to the results, Dato-DXd demonstrated an overall response rate of 43 percent, with durable responses and a manageable safety profile. Joining Dr. Jacob Sands to talk more about these findings and their implications are Drs. Elaine Shum and Estelamari Rodriguez. Dr. Shum is an Assistant Professor in the Department of Medicine at NYU Grossman School of Medicine, and Dr. Rodriguez is an Associate Director of Community Outreach, Thoracic Oncology at Sylvester Comprehensive Cancer Center at the University of Miami Health System.

Host: Gerard A. Silvestri MD, MS, Master FCCP

Guest: Anurag Singh, MD

Guest: Adam H. Fox, MD, MSc

Guest: Mariam Alexander, MD, PhD

Recent therapeutic advances are reshaping our approach to limited-stage small cell lung cancer. In this multidisciplinary discussion, Dr. Gerard Silvestri sits down with Drs. Adam Fox, Mariam Alexander, and Anurag Singh to explore the evolving standard of care and practical considerations for timely and effective care. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York.

This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Host: Gerard A. Silvestri MD, MS, Master FCCP

Guest: Anurag Singh, MD

Guest: Adam H. Fox, MD, MSc

Guest: Mariam Alexander, MD, PhD

Despite the typically poor prognosis of extensive-stage small cell lung cancer, recent advancements are reshaping clinical perspectives on treatment. New and emerging options show promise for prolonged survival and improved quality of life. Join Drs. Gerard Silvestri, Adam Fox, Mariam Alexander, and Anurag Singh as they discuss how the therapeutic landscape is evolving for these patients. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York.

This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.